This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Vivity is the first and only wavefront-shaping IOL with Alcon’s proprietary X-WAVE Technology
The average time of dilation lasts three to eight hours
Application based on results from the TROPION-Breast01 Phase III trial
This acquisition enables MTD to open new, strategic markets
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
Subscribe To Our Newsletter & Stay Updated
